Want to see AU:OSS full AI Analyst Report?
Top Page
Stemcell United Ltd.
(Sydney:OSS)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.02
▲(15.38% Upside)
Action:Reiterated
Date:10/02/26
The score is primarily weighed down by weak financial performance, including persistent losses, negative equity, and ongoing cash burn despite a revenue rebound. Limited technical data reduces confidence in any trend assessment, and valuation is difficult to support due to a negative P/E and no dividend information.
Positive Factors
Revenue Rebound
The sharp FY2026 revenue rebound indicates materially improved commercial traction and a larger operating base. If retained, this growth can improve operating leverage and support future margin recovery, although the increase started from a very low prior-year level.
Negative Factors
Persistent Unprofitability
Negative gross profit and a roughly -52% net margin show that current revenue is not covering the economics of the business. Without a durable improvement in pricing, costs, or product mix, continued losses could offset the benefits of revenue growth and prolong dependence on outside capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Rebound
The sharp FY2026 revenue rebound indicates materially improved commercial traction and a larger operating base. If retained, this growth can improve operating leverage and support future margin recovery, although the increase started from a very low prior-year level.
Read all positive factors
Stemcell United Ltd. (OSS) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$3.29M
Dividend YieldN/A
Average Volume (3M)221.41K
Price to Earnings (P/E)―
Beta (1Y)-0.48
Revenue Growth877.51%
EPS Growth67.42%
CountryAU
Employees31
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.00
Shares Outstanding235,350,170
10 Day Avg. Volume240,256
30 Day Avg. Volume221,415
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-3.09
Price to Sales (P/S)0.78
P/FCF Ratio-1.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Stemcell United Ltd. Business Overview & Revenue Model
Company Description
BPH Global Ltd, along with its associated entities, specializes in the procurement, production, promotion, and sale of traditional medicinal items. Its operational reach spans Australia, Singapore, China, and the broader Southeast Asian market. Th...
How the Company Makes Money
null...
Stemcell United Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
15
Very Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.44M | 352.38K | 109.97K | 339.00 | 14.35M |
| Gross Profit | -890.49K | -678.01K | 18.27K | 339.00 | 2.29M |
| EBITDA | -1.76M | -1.45M | -1.76M | -3.52M | -2.49M |
| Net Income | -1.79M | -1.49M | -2.27M | -4.32M | -3.54M |
Balance Sheet | |||||
| Total Assets | 1.38M | 541.00K | 691.84K | 2.10M | 7.16M |
| Cash, Cash Equivalents and Short-Term Investments | 259.88K | 152.74K | 134.82K | 1.14M | 685.56K |
| Total Debt | 555.74K | 0.00 | 508.64K | 0.00 | 1.30M |
| Total Liabilities | 2.26M | 2.01M | 1.97M | 1.19M | 2.44M |
| Stockholders Equity | -868.82K | -1.45M | -966.82K | 530.13K | 3.20M |
Cash Flow | |||||
| Free Cash Flow | -2.14M | -932.18K | -1.26M | -1.49M | -4.93M |
| Operating Cash Flow | -2.14M | -929.81K | 0.00 | 0.00 | 0.00 |
| Investing Cash Flow | -8.38K | -2.37K | 185.33K | 6.29K | -914.21K |
| Financing Cash Flow | 2.44M | 962.99K | 697.04K | 1.38M | 281.27K |
Stemcell United Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | AU$2.74B | -32.31 | -10.06% | ― | 555.67% | 49.08% | |
52 Neutral | AU$14.72M | -2.06 | -247.44% | ― | -4.24% | 33.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$208.38M | -14.43 | -36.83% | ― | 51.07% | -47.63% | |
41 Neutral | AU$3.29M | -3.17 | 216.63% | ― | 877.51% | 67.42% | |
40 Underperform | AU$18.25M | -4.44 | -132.20% | ― | ― | -200.00% | |
39 Underperform | AU$2.68M | -0.29 | -607.23% | ― | ― | 13.50% |
* Healthcare Sector Average
AU:OSS
Stemcell United Ltd.
0.02
>-0.01
-20.00%
AU:CYP
Cynata Therapeutics Limited
0.01
-0.21
-95.11%
AU:1AI
Living Cell Technologies
0.01
0.00
0.00%
AU:MSB
Mesoblast Limited
2.07
-0.69
-25.00%
AU:OCC
Orthocell Ltd
0.77
-0.71
-47.96%
AU:CMB
Regeneus Ltd.
0.52
0.01
1.96%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.